Indian Journal of Gynecologic Oncology (IJGO) is the official publication of the Association of Gynecological Oncologists of India (AGOI) that considers for publications, articles in all fields of gynecological oncology. In addition to gynecological oncology, articles pertaining to breast oncology are also accepted.
IJGO is a double-blind, peer-reviewed journal featuring articles written by clinicians, clinical researchers and basic scientists. It is dedicated to research and patient care issues with global reach and is edited by renowned national and international experts in the field of gynecological oncology.
This journal adheres to international scholarly publishing standards and follows publishing ethics stringently. It focuses on the complete spectrum of contemporary clinical and basic science related issues in the field of pediatric, adult and geriatric gynecological oncology, including all subspecialties of gynecological oncology encompassing surgical, medical oncology, radiation oncology and pathology, imaging and allied sciences, new and emerging technologies, cutting-edge innovations and future trends in gynecological oncology.
This journal provides a platform for the publication of high-quality clinical and experimental studies, thereby documenting recent advances and new developments in all fields of gynecological oncology.
The editorial board of IJGO comprises of clinicians with highest academic reputation, professors, university teachers, researchers, PhD holders across the globe in various fields of gynecological oncology, breast oncology, medical oncology, surgical oncology, radiation oncology, preventive medicine, pain and palliative medicine, lab researchers, researchers dealing with patient advocacy group and rehabilitation in the field of gynecological oncology.
There is a separate section of international overseas editors of high reputation, both from developed and developing countries across all continents.
The journal publishes original research articles, editorials, reviews, consensus guidelines for diagnosis and treatment of gynecological oncology, letter to the editor, images in gynecological oncology, invited editorials, and controversies in contemporary issues.
To ensure objectivity and transparency in research and to ensure that accepted principles of ethical and professional conduct have been followed, authors should include information regarding sources of funding, potential conflicts of interest (financial or non-financial), informed consent if the research involved human participants, and a statement on welfare of animals if the research involved animals.
Once a manuscript is submitted online to the journal site, the initial step is a technical check by the publisher who also assesses the article for completeness, adherence to instructions for authors, inclusion of ethics and competing interest’s statements. Articles that pass the completeness are transferred to the Editor in Chief who, after an initial appraisal, assigns the manuscript to one of the Associate Editors. Based on the overall opinion, articles may be rejected at the initial stage by the Editor in Chief or by the Associate Editors, or may be sent out by the latter for peer review. Often the Associate Editors themselves contribute to a detailed peer-review of the manuscripts.
For external peer review, the journal adheres to a double-blind process that mandates review of all original research and review manuscripts by at least two/three experts in the journal's reviewer database. Clear and concise guidance is provided to the reviewers and periodic feedback is sought to maintain uniformity and objectiveness of the peer review process.
All review comments received are consolidated by the handling Associate Editor and transmitted by them to the Editor in Chief with her/his own recommendation. The Editor in Chief then takes a final decision. If the decision is to revise, the comments are then sent to the corresponding author. The revised version is sent out again for review (s) till the article meets the requisite acceptance standards of the journal. Occasionally, for articles designated for special issues, or deemed to be of high interest, rapid peer review is undertaken by a minimum of three editorial board members (always including the Editor in Chief) to reduce the turnaround time without compromising the rigorousness of the process.
- SP Somashekhar
- Publishing model
- Hybrid. Open Access options available
- 35 days
- Submission to first decision
- 54 days
- Submission to acceptance
- 7,343 (2019)
Authors (first, second and last of 6)
Authors (first, second and last of 5)
Expression of ER/PR Receptor, Her-2/neu, Ki67 and p53 in Endometrial Carcinoma: Clinicopathological Implication and Prognostic Value
As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
About this journal
- Electronic ISSN
- Print ISSN
- Abstracted and indexed in
- EBSCO Discovery Service
- Emerging Sources Citation Index
- Google Scholar
- INIS Atomindex
- Institute of Scientific and Technical Information of China
- Japanese Science and Technology Agency (JST)
- OCLC WorldCat Discovery Service
- ProQuest-ExLibris Primo
- ProQuest-ExLibris Summon
- Semantic Scholar
- UGC-CARE List (India)